• Bobcat339: TET Inhibition for DNA Methylation Studies

  2026-09-17

  Bobcat339 is a cytosine structure-based TET enzyme inhibitor for separating TET1/TET2-dependent DNA demethylation from broader methyltransferase effects. This practical guide connects biochemical screening, MSC osteogenesis assays, methylation profiling, and multi-omics validation while emphasizing dose selection and interpretation limits.

• Cucurbitacin I: A Precision STAT3 Perturbation Guide

  2026-09-16

  Cucurbitacin I, also known as JSI-124, provides a focused way to interrogate JAK2/STAT3 biology in cancer models. This guide combines pathway-level assay design with lessons from human SAN-plexus assembloids to improve mechanistic interpretation without overextending cross-domain evidence.

• Amphotericin B for Fungal Infection Research

  2026-09-16

  Build more informative fungal infection research workflows with Amphotericin B by separating direct membrane damage from biofilm-associated resistance and host-cell signaling. This guide connects dose-response testing, Candida albicans biofilm assays, PP2A–autophagy experiments, and troubleshooting into one practical framework.

• Docetaxel Resistance: From Microtubules to the Microbiome

  2026-09-15

  Docetaxel resistance is not only a problem of microtubule biology. Evidence linking gut dysbiosis, intratumoral lipopolysaccharide, and the NF-κB–IL6–STAT3 axis suggests a broader translational framework for studying Taxotere response. This article outlines how to connect molecular pharmacology, microbiome-aware models, and experimental strategy without overstating early evidence.

• Separating Growth Inhibition from Cell Death in Cancer Model

  2026-09-15

  Hannah R. Schwartz’s dissertation shows why relative viability and fractional viability should not be treated as interchangeable measures of anticancer activity. Its central contribution is a framework for distinguishing proliferative arrest from actual cell killing while accounting for differences in response magnitude and timing.

• LNP Surface Charge and V-ATPase Drive Delivery

  2026-09-14

  This 2026 study proposes that LNP tropism is determined by a synergy between nanoparticle surface charge and the V-ATPase activity of recipient cells. Its in vitro and in vivo experiments connect cellular endo/lysosomal state with charge-dependent delivery, offering a mechanistic framework for interpreting liver and lung targeting.

• GDC-0941: Reliable PI3K/Akt Assay Workflows

  2026-09-14

  This scenario-driven guide explains how GDC-0941 (SKU A8210) can improve the interpretation and reproducibility of PI3K/Akt pathway inhibition, viability, proliferation, and apoptosis workflows. It covers mechanism, solvent handling, protocol parameters, endpoint selection, and practical vendor evaluation for biomedical laboratories.

• AZD1480: A Translational Compass for JAK2/STAT3

  2026-09-13

  AZD1480 provides a focused way to interrogate tumor-intrinsic JAK2/STAT3 signaling, particularly when immune or metabolic interventions unexpectedly create compensatory survival signals. This thought-leadership guide connects its ATP-competitive pharmacology with biomarker strategy, model selection, combination design, and the limitations that matter for translational oncology.

• LRRC8A–Caveolin-1 Signaling in PDAC

  2026-09-12

  The reference study identifies a cholesterol-dependent LRRC8A–Caveolin-1 complex that links cell-volume regulation with KRAS/EGFR signaling, ribosome biogenesis, and pancreatic ductal adenocarcinoma growth. Its integrated use of genetic perturbation, pharmacological inhibition, xenografts, and patient-derived organoids provides a framework for connecting membrane organization to biosynthetic expansion.

• AZD1390: Decoding ATM Dependence Under G4 Stress

  2026-09-11

  Explore how AZD1390, a selective ATM kinase inhibitor, can distinguish DNA damage signaling from G-quadruplex replication stress. This assay-centered framework supports more rigorous glioblastoma radiosensitization and cancer research.

• Tunicamycin for ER Stress Assay Design

  2026-09-11

  Discover how Tunicamycin functions as an N-glycosylation inhibitor and controlled ER stress model. This guide connects glycosylation blockade with HCV-related insulin-resistance research and practical assay design decisions.

• Bay 11-7821 for NF-κB Assay Design

  2026-09-10

  Bay 11-7821, also called BAY 11-7082, provides a practical pharmacological handle for separating NF-κB-dependent inflammation from macrophage HMGB1 release, apoptosis, and tumor-cell phenotypes. This guide connects inhibitor handling, dose selection, reporter assays, exosome workflows, and troubleshooting to the lactate-driven sepsis biology described in the reference study.

• Phosbind Acrylamide for Phosphorylation Analysis

  2026-09-10

  Phosbind Acrylamide enables antibody-free visualization of phosphorylation-dependent mobility shifts in proteins, supporting faster screening of signaling changes and kinase activity. This workflow translates annexin A2 disease-mechanism findings into practical, paired-gel experiments for protein phosphorylation analysis.

• BMAL1 Phase Separation and Circadian Transcription

  2026-09-09

  Gao et al. identify BMAL1 as a phosphorylation-regulated phase-separating protein that forms dynamic nuclear condensates serving as transcriptional hubs. The study connects BMAL1 intrinsically disordered regions, E-box DNA, transcriptional cofactor recruitment, rhythmic gene expression, and locomotor behavior, while suggesting practical tests for phosphorylation-dependent regulation.

• FITC-Concanavalin A (ConA) Conjugate

  2026-09-09

  FITC-Concanavalin A (ConA) Conjugate is a fluorescent lectin conjugate for visualizing accessible α-D-glucose and α-D-mannose residues on glycoproteins and glycolipids in cell or tissue samples. It supports cell surface carbohydrate detection, immunofluorescence staining, and flow cytometry, but should not be treated as a universal glycan marker or used to identify non-carbohydrate targets.

7911 records 1/528 page Next 12345 下5页 Last page